Cerebras IPO Upsized Amid Strong Demand

Cerebras IPO was upsized on May 11, 2026 as demand surged, expanding the offering and valuation and drawing near-term trading interest for Nasdaq debut.

May 11, 2026·1 min read
View all news articles
Flat filled vector of an AI chip with expanding circuitry to symbolize the Cerebras IPO upsizing and investor demand.

KEY TAKEAWAYS

  • Cerebras raised its IPO to 30 million shares at a $150-$160 price range.
  • Upsize pushed potential gross proceeds to $4.5-$4.8 billion.
  • Demand topped 20x the shares offered, implying a fully diluted valuation near $48.8 billion.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Cerebras Systems increased its IPO terms on May 11, 2026, after strong investor demand, expanding the offering and positioning the Sunnyvale chip maker for a Nasdaq listing and a larger capital raise.

Upsized Offering Reflects Investor Demand

Cerebras Systems, based in Sunnyvale, California, designs semiconductors, supercomputers, and artificial intelligence (AI) services. The company raised its planned IPO to 30 million Class A shares, priced between $150 and $160 per share, potentially generating $4.5 billion to $4.8 billion in gross proceeds. Investor demand exceeded twenty times the shares offered, prompting underwriters to expand the deal.

The upsized terms imply a fully diluted valuation of up to $48.8 billion, reflecting strong appetite for AI chip developers in the market.

Deal Process and Nasdaq Listing

An amended S-1 filing on May 4, 2026, had proposed selling 28 million Class A shares at $115 to $125 per share. Joint bookrunners on the offering include Morgan Stanley, Citigroup, Barclays, and UBS Investment Bank, with Mizuho Securities and TD Securities among other underwriters.

The company plans to list on Nasdaq under the ticker CBRS and expects to set the final IPO price on May 13, 2026.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Tango Therapeutics Vopimetostat Results Spur Phase 3

Tango Therapeutics Vopimetostat Results Spur Phase 3

Tango Therapeutics vopimetostat results push the program toward Phase 3 after strong pancreatic-cancer activity, prompting heavy share trading.

SpaceX IPO Fixes Price, Draws Heavy Demand

SpaceX IPO Fixes Price, Draws Heavy Demand

SpaceX IPO sets a fixed $135 price and drew heavy orders, creating allocation and liquidity questions that could shape first-day trading and index flows.

Cerebras Stock Climbs After Wall Street Buy Calls

Cerebras Stock Climbs After Wall Street Buy Calls

Cerebras stock rallied after nine brokerages initiated coverage on June 8, 2026, supporting a near-term rerating as analysts cited wafer-scale chips.

Intel Stock Surges on Reported Google, Nvidia Foundry Deals

Intel Stock Surges on Reported Google, Nvidia Foundry Deals

Intel stock surges after reports of Google TPU orders and Nvidia tests of Intel's advanced process; lack of filings raises verification risk for traders.

SanDisk Stock Climbs Then Pulls Back After Upgrades

SanDisk Stock Climbs Then Pulls Back After Upgrades

SanDisk stock drew June 8 analyst 12-month target lifts after an April blockbuster quarter; traders weigh May AI gains versus NAND supply concerns.

Ingredion Tate & Lyle Takeover Agreed

Ingredion Tate & Lyle Takeover Agreed

Ingredion Tate & Lyle takeover is an all-cash $3.6 billion offer that preserves dividends, wins 17.1% undertakings and tightens near-term deal certainty.